- Title
- B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers
- Creator
- McLachlan, Tabitha; Matthews, William C.; Dun, Matthew D.; Jackson, Evangeline R.; Staudt, Dilana E.; Douglas, Alicia M.; Findlay, Izac J.; Persson, Mika L.; Duchatel, Ryan J.; Mannan, Abdul; Germon, Zacary P.
- Relation
- Molecular Cancer Research Vol. 20, Issue 12, p. 1711-1723
- Publisher Link
- http://dx.doi.org/10.1158/1541-7786.MCR-22-0567
- Publisher
- American Association for Cancer Research
- Resource Type
- journal article
- Date
- 2022
- Description
- B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of the tumor suppressor TP53, conferring survival, protection, and maintenance of lymphoma cells. BCL6 expression in normal B cells is fundamental in the regulation of humoral immunity, via initiation and maintenance of the germinal centers (GC). Its role in B cells during the production of high affinity immunoglobins (that recognize and bind specific antigens) is believed to underpin its function as an oncogene. BCL6 is known to drive the self-renewal capacity of leukemia-initiating cells (LIC), with high BCL6 expression in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and glioblastoma (GBM) associated with disease progression and treatment resistance. The mechanisms underpinning BCL6-driven therapy resistance are yet to be uncovered; however, high activity is considered to confer poor prognosis in the clinical setting. BCL6's key binding partner, BCL6 corepressor (BCOR), is frequently mutated in pediatric cancers and appears to act in concert with BCL6. Using publicly available data, here we show that BCL6 is ubiquitously overexpressed in pediatric brain tumors, inversely to BCOR, highlighting the potential for targeting BCL6 in these often lethal and untreatable cancers. In this review, we summarize what is known of BCL6 (role, effect, mechanisms) in pediatric cancers, highlighting the two sides of BCL6 function, humoral immunity, and tumorigenesis, as well as to review BCL6 inhibitors and highlight areas of opportunity to improve the outcomes of patients with pediatric cancer.
- Subject
- humoral immunity; pediatric cancers; adult; lymphoma cells; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1485194
- Identifier
- uon:51515
- Identifier
- ISSN:1557-3125
- Rights
- x
- Language
- eng
- Reviewed
- Hits: 701
- Visitors: 701
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|